What genotypes of lung cancer can osimertinib be used to treat?

Osimertinib is a highly effective targeted drug for lung cancer, especially for patients with certain genotypes of non-small cell lung cancer (NSCLC).

1.EGFRT790MMutation-positive lung cancer:

Osimertinib is mainly used to treat adult patients with locally advanced or metastatic non-small cell lung cancer who have disease progression during or after previous treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and who have been confirmed to have EGFRT790M mutation-positive disease. Patients with this genotype often develop resistance after treatment with traditional EGFR inhibitors, and osimertinib can effectively inhibit this resistance mutation, thereby controlling the progression of the disease.

2.EGFRSensitive mutation-positive lung cancer:

In addition toEGFRT790Mmutation, osimertinib is also suitable for the initial treatment of EGFR sensitive mutation-positive locally advanced or metastatic non-small cell lung cancer. These sensitive mutations include, but are not limited to, exon 19 deletion and L858R point mutation. Osimertinib inhibits tumor cell proliferation by irreversibly binding to these mutants.

3.The activity against wild-type EGFR is weak:

It is worth noting that although osimertinib has anti-tumor effects on non-small cell lung cancer cell lines carrying EGFR mutations, its anti-tumor activity is relatively weak against wild-type EGFR gene amplification. This means that for those patients who do not have EGFR mutations, the therapeutic effect of osimertinib may not be significant.

4.Other related gene mutations:

In addition to the major EGFR mutations mentioned above, osimertinib can also inhibit HER2 and HER3 at clinical concentrations. , HER4, ACK1 and BLK activities. These genes are also closely related to the occurrence and development of lung cancer, so osimertinib may also have a certain therapeutic effect on patients with these genotypes.